Windward Bio files for U.S. IPO as biotech listings regain momentum

Top Stories

Editors' Picks

Stocks

Crypto

Economics

Currencies

Commodities

Business & Wealth

Market Voices

Darina Pashchenko

24.10.2026

Windward Bio files for U.S. IPO as biotech listings regain momentum — Windward Bio eyes IPO

Biotech companies are among the more active issuers in this fall's IPO market, despite rising bond yields and concerns about the AI trade weighing on broader risk appetite. Windward Bio joins that pipeline with plans to raise its profile among public market investors as it advances antibody treatments for respiratory and inflammatory diseases.

Highlights

Windward Bio filed for a U.S. IPO to list on Nasdaq under 'WWB', targeting funds for antibody treatments for asthma and inflammatory diseases.
Windward secured up to $365 million from investors including OrbiMed, Novo Holdings, Omega Funds, and Blue Owl Healthcare Opportunities prior to the IPO.
Novo Holdings and Blue Owl Capital hold pre-IPO stakes of 14.5% and 5.9% in Windward, as biotech IPOs accelerate amid cautious broader market sentiment.

Listing plan and drug pipeline

As reported by Reuters, Windward Bio filed on Friday for an initial public offering in the U.S. as it seeks to tap renewed investor interest in biotech listings.

The Basel, Switzerland-based company is developing long-lasting antibody treatments for asthma, chronic obstructive pulmonary disease and inflammatory skin conditions, with the goal of reducing how often patients need injections.

Its lead drug candidate, WIN378, is an antibody designed to block thymic stromal lymphopoietin, or TSLP, a protein that triggers several inflammatory pathways involved in asthma and other respiratory diseases. Windward plans to list its shares on Nasdaq under the symbol "WWB".

Jefferies, TD Cowen, Piper Sandler and UBS Investment Bank are serving as underwriters for the offering.

Investor backing and sector backdrop

Windward has secured up to $365 million from investors including OrbiMed, Novo Holdings, Omega Funds and Blue Owl Healthcare Opportunities, giving it a sizable capital base ahead of the planned market debut.

Novo Holdings and funds managed by Blue Owl Capital hold pre-IPO stakes of 14.5% and 5.9%, respectively, in the company.

The filing comes as biotech remains one of the more active sectors in this year's fall IPO market, even as broader market sentiment faces pressure from higher bond yields and caution around AI-related trades.

Our earlier article on Chariot Claims’ $10 million Series A detailed how the legal tech startup is using fresh funding to hire, build AI-driven case review tools, and scale high-volume consumer claim processing with partner law firms. We also noted that legal tech investment has stayed elevated, as investors continue backing software platforms that automate workflows and expand capacity in specialized services.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

#Biotechnology

Editor's Picks for You

The great sell-off: Why companies are dumping Bitcoin

By Pavlo Kot
4 hours ago

The great sell-off: Why companies are dumping Bitcoin

Editors' Picks

Trustee Founder Vadym Hrusha: The future of crypto payments belongs to AI agents

By Pavlo Kot
Yesterday

Trustee Founder Vadym Hrusha: The future of crypto payments belongs to AI agents

Editors' Picks

China’s crypto paradox: A booming market despite the ban?

By Alena Volkova
Yesterday

China’s crypto paradox: A booming market despite the ban?

Editors' Picks

All Editors' Top Picks

Latest Biotechnology News

Marine Biomedical secures FDA clearance for PearlBone in U.S. orthopaedic market

By Sholanke Dele
Yesterday

Marine Biomedical secures FDA clearance for PearlBone in U.S. orthopaedic market

Companies

#USA #Australia #Biotechnology #Healthcare Industry

Windward Bio reaches $1.07 billion valuation in Nasdaq debut

By Oleksii Zaichenko
Yesterday

Windward Bio reaches $1.07 billion valuation in Nasdaq debut

Companies

Amundi Global Bioenergy UCITS ETF reports net asset value on London Stock Exchange

By Darina Pashchenko
13.11.2026

Amundi Global Bioenergy UCITS ETF reports net asset value on London Stock Exchange

Financial Institutions

#UK #LSE #Trading #Biotechnology

All Biotechnology News

Pavlo Kot
4 hours ago

The great sell-off: Why companies are dumping Bitcoin

Pavlo Kot
Yesterday

Trustee Founder Vadym Hrusha: The future of crypto payments belongs to AI agents

Alena Volkova
Yesterday

China’s crypto paradox: A booming market despite the ban?

Mikhail Vnuchkov
13.11.2026

Global Microsoft outage: What happened and how serious is it?

Dmytro Kharkov
13.11.2026

Meme stocks vs. memecoins: Same viral frenzy, different endgames

Pavlo Kot
41 min ago

Jesse Cohen: Top five developments to watch in U.S. stock market this week

Daria Chernytska
50 min ago

Behavioral Finance: Victor Ricciardi co-edits book on investor behavior and psychology

Yulia Slavina
1 hour ago

Quinten Francois: Bitcoin and Ethereum underperform S&P 500 over five years

Eugene Komchuk
1 hour ago

Late shorters in bitcoin will face severe consequences, Ivan Liljeqvist warns

Igor Krasulya
1 hour ago

Stefan Schubert: Central Stockholm flat prices up to 9 times higher than suburbs

Top News

Mélissa Bac
1 hour ago

Nvidia’s post-Huang era begins under growing pressure from Washington

Nvidia’s post-Huang era begins under growing pressure from Washington

Ezequiel Gomes
1 hour ago

AI infrastructure stocks lose $4.2T as debt and valuation fears grow

AI infrastructure stocks lose $4.2T as debt and valuation fears grow

Pavlo Kot
4 hours ago

The great sell-off: Why companies are dumping Bitcoin

The great sell-off: Why companies are dumping Bitcoin

Jainam Mehta
21 hours ago

Goldman Sachs forecasts 19% return for Asian stocks in 2027

Goldman Sachs forecasts 19% return for Asian stocks in 2027

Sholanke Dele
Yesterday

Oil prices fall nearly 25% in a month despite Iranian tanker attacks

Oil prices fall nearly 25% in a month despite Iranian tanker attacks

Top 5 companies for you

United States

Live News

Mykhailo Ihnatenko
Now

AMD stock faces profit-taking risk as AI momentum builds

Olga Shendetskaya
Now

Eurozone economy outperforms expectations, strengthening case for ECB rate hike

Anton Kharitonov
Now

EUR/USD remains under pressure as dollar strength threatens a drop to 1.1000

Mykhailo Ihnatenko
Now

Ethereum drops below $2,000: Can ETH recover amid $1.64 billion in crypto liquidations?

Pavlo Kot
Now

Indian authorities raid CoinDCX and Delta Exchange over suspicious crypto transactions

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.